Tags Archive Navigation
icon
-
StoryThe art of drug design in a technological age
-
StoryTo make a difference, start with patients
-
Media ReleaseNovartis Provides Update on AVXS-101 Intrathecal Clinical Development Program
-
Media ReleaseNovartis received European Medicines Agency (EMA) PRIME designation for iptacopan (LNP) in C3 glomerulopathy (C3G)
-
Media ReleaseEn 2020, Novartis a enregistré une croissance de son chiffre d’affaires et de sa marge; il a continué de faire progresser sa prochaine vague de médicaments
-
Media ReleaseNovartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben
-
Media ReleaseNovartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020.
-
Media ReleaseNovartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19
-
Media ReleaseNovartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD
-
Media ReleaseNovartis provides update on FDA review of ofatumumab, a self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
-
StoryToward regrowing cartilage
-
StoryGoing the extra mile to keep clinical trials on track during the COVID-19 pandemic